Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Groen

Showing results (441-450 of 564) with videos related to

Pageof 57
Sort By:
Thorax|December 29, 2018
Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening studyJoan E Walter, Marjolein A Heuvelmans, Kevin Ten Haaf, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|September 24, 2014
Attention-deficit/hyperactivity disorder polygenic risk scores predict attention problems in a population-based sample of childrenMaria M Groen-Blokhuis, Christel M Middeldorp, Kees-Jan Kan, et al.
EJNMMI Research|May 10, 2021
Necrosis binding of Ac-Lys<sup>0</sup>(IRDye800CW)-Tyr<sup>3</sup>-octreotate: a consequence from cyanine-labeling of small moleculesMarcus C M Stroet, Bianca M Dijkstra, Sebastiaan E Dulfer, et al.
Neuro-Oncology|October 31, 2023
Emotion recognition in relation to tumor characteristics in patients with low-grade gliomaFemke F Siebenga, Hiska L van der Weide, Floor Gelmers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Molecular Tumor Boards: current practice and future needsD L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trialH Kievit, M B Muntinghe-Wagenaar, L B M Hijmering-Kappelle, et al.
Psycho-Oncology|October 15, 2025
Distinguishing Mental From Physical Fatigue in Patients With Low-Grade GliomaFemke F Siebenga, Sandra E Rakers, Floor Gelmers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2010
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imagingA-M C Dingemans, A J de Langen, V van den Boogaart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic AnalysisDavid Planchard, Benjamin Besse, Harry J M Groen, et al.
Plos One|August 31, 2017
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progressionA J van der Wekken, J L Kuiper, A Saber, et al.
Pageof 57

Showing results (441-450 of 564) with videos related to

Sort By:
Pageof 57
Thorax|December 29, 2018
Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening studyJoan E Walter, Marjolein A Heuvelmans, Kevin Ten Haaf, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|September 24, 2014
Attention-deficit/hyperactivity disorder polygenic risk scores predict attention problems in a population-based sample of childrenMaria M Groen-Blokhuis, Christel M Middeldorp, Kees-Jan Kan, et al.
EJNMMI Research|May 10, 2021
Necrosis binding of Ac-Lys<sup>0</sup>(IRDye800CW)-Tyr<sup>3</sup>-octreotate: a consequence from cyanine-labeling of small moleculesMarcus C M Stroet, Bianca M Dijkstra, Sebastiaan E Dulfer, et al.
Neuro-Oncology|October 31, 2023
Emotion recognition in relation to tumor characteristics in patients with low-grade gliomaFemke F Siebenga, Hiska L van der Weide, Floor Gelmers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Molecular Tumor Boards: current practice and future needsD L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trialH Kievit, M B Muntinghe-Wagenaar, L B M Hijmering-Kappelle, et al.
Psycho-Oncology|October 15, 2025
Distinguishing Mental From Physical Fatigue in Patients With Low-Grade GliomaFemke F Siebenga, Sandra E Rakers, Floor Gelmers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2010
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imagingA-M C Dingemans, A J de Langen, V van den Boogaart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic AnalysisDavid Planchard, Benjamin Besse, Harry J M Groen, et al.
Plos One|August 31, 2017
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progressionA J van der Wekken, J L Kuiper, A Saber, et al.
Pageof 57